| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA1136: bevacizumab (originator and biosimilars) with fluoropyrimidine-based chemotherapy for metastatic colorectal cancer |
|
Medicine details |
|
| Medicine name | bevacizumab (Avastin® and biosimilars) |
| Formulation | 25mg/ml concentrate for solution for infusion |
| Reference number | 6720 |
| Indication | Treatment with fluoropyrimidine-based chemotherapy for metastatic colorectal cancer |
| Company | Roche |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 25/02/2026 |
| NICE guidance | |